Clinical protocols used to inhibit the growth or spread of NEOPLASMS.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy.
It is a form of protection provided by law. In the United States this protection is granted to authors of original works of authorship, including literary, dramatic, musical, artistic, and certain other intellectual works. This protection is available to both published and unpublished works. (from Circular of the United States Copyright Office, 6/30/2008)
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Techniques for standardizing and expediting taxonomic identification or classification of organisms that are based on deciphering the sequence of one or a few regions of DNA known as the "DNA barcode".
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Systematic and thorough inspection of the patient for physical signs of disease or abnormality.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
Alkaloids derived from TYRAMINE combined with 3,4-dihydroxybenzaldehyde via a norbelladine pathway, including GALANTAMINE, lycorine and crinine. They are found in the Amaryllidaceae (LILIACEAE) plant family.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
The type species of RUBULAVIRUS that causes an acute infectious disease in humans, affecting mainly children. Transmission occurs by droplet infection.
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Two or more vaccines in a single dosage form.
Compression of the ULNAR NERVE in the cubital tunnel, which is formed by the two heads of the flexor carpi ulnaris muscle, humeral-ulnar aponeurosis, and medial ligaments of the elbow. This condition may follow trauma or occur in association with processes which produce nerve enlargement or narrowing of the canal. Manifestations include elbow pain and PARESTHESIA radiating distally, weakness of ulnar innervated intrinsic hand muscles, and loss of sensation over the hypothenar region, fifth finger, and ulnar aspect of the ring finger. (Joynt, Clinical Neurology, 1995, Ch51, p43)
Entrapment of the distal branches of the posterior TIBIAL NERVE (which divides into the medial plantar, lateral plantar, and calcanial nerves) in the tarsal tunnel, which lies posterior to the internal malleolus and beneath the retinaculum of the flexor muscles of the foot. Symptoms include ankle pain radiating into the foot which tends to be aggravated by walking. Examination may reveal Tinel's sign (radiating pain following nerve percussion) over the tibial nerve at the ankle, weakness and atrophy of the small foot muscles, or loss of sensation in the foot. (From Foot Ankle 1990;11(1):47-52)
A syndrome associated with inflammation of the BRACHIAL PLEXUS. Clinical features include severe pain in the shoulder region which may be accompanied by MUSCLE WEAKNESS and loss of sensation in the upper extremity. This condition may be associated with VIRUS DISEASES; IMMUNIZATION; SURGERY; heroin use (see HEROIN DEPENDENCE); and other conditions. The term brachial neuralgia generally refers to pain associated with brachial plexus injury. (From Adams et al., Principles of Neurology, 6th ed, pp1355-6)
Ulnar neuropathies caused by mechanical compression of the nerve at any location from its origin at the BRACHIAL PLEXUS to its terminations in the hand. Common sites of compression include the retroepicondylar groove, cubital tunnel at the elbow (CUBITAL TUNNEL SYNDROME), and Guyon's canal at the wrist. Clinical features depend on the site of injury, but may include weakness or paralysis of wrist flexion, finger flexion, and ulnar innervated intrinsic hand muscles, and impaired sensation over the ulnar aspect of the hand, fifth finger, and ulnar half of the ring finger. (Joynt, Clinical Neurology, 1995, Ch51, p43)
Congenital structural abnormalities and deformities of the musculoskeletal system.
Conditions characterized by pain involving an extremity or other body region, HYPERESTHESIA, and localized autonomic dysfunction following injury to soft tissue or nerve. The pain is usually associated with ERYTHEMA; SKIN TEMPERATURE changes, abnormal sudomotor activity (i.e., changes in sweating due to altered sympathetic innervation) or edema. The degree of pain and other manifestations is out of proportion to that expected from the inciting event. Two subtypes of this condition have been described: type I; (REFLEX SYMPATHETIC DYSTROPHY) and type II; (CAUSALGIA). (From Pain 1995 Oct;63(1):127-33)
The part of a limb or tail following amputation that is proximal to the amputated section.
A structurally-related group of signaling proteins that are phosphorylated by the INSULIN RECEPTOR PROTEIN-TYROSINE KINASE. The proteins share in common an N-terminal PHOSPHOLIPID-binding domain, a phosphotyrosine-binding domain that interacts with the phosphorylated INSULIN RECEPTOR, and a C-terminal TYROSINE-rich domain. Upon tyrosine phosphorylation insulin receptor substrate proteins interact with specific SH2 DOMAIN-containing proteins that are involved in insulin receptor signaling.
A cell surface receptor for INSULIN. It comprises a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The receptor contains an intrinsic TYROSINE KINASE domain that is located within the beta subunit. Activation of the receptor by INSULIN results in numerous metabolic changes including increased uptake of GLUCOSE into the liver, muscle, and ADIPOSE TISSUE.
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability.
Analog or digital communications device in which the user has a wireless connection from a telephone to a nearby transmitter. It is termed cellular because the service area is divided into multiple "cells." As the user moves from one cell area to another, the call is transferred to the local transmitter.
Professionals qualified by graduation from an accredited school of nursing and by passage of a national licensing examination to practice nursing. They provide services to patients requiring assistance in recovering or maintaining their physical or mental health.
Messages between computer users via COMPUTER COMMUNICATION NETWORKS. This feature duplicates most of the features of paper mail, such as forwarding, multiple copies, and attachments of images and other file types, but with a speed advantage. The term also refers to an individual message sent in this way.
Studies designed to assess the efficacy of programs. They may include the evaluation of cost-effectiveness, the extent to which objectives are met, or impact.
The process of formulating, improving, and expanding educational, managerial, or service-oriented work plans (excluding computer program development).
Encouraging consumer behaviors most likely to optimize health potentials (physical and psychosocial) through health information, preventive programs, and access to medical care.
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.

Study on chemoprevention of hepatocellular carcinoma by ginseng: an introduction to the protocol. (1/58)

In patients with chronic hepatitis C virus disease, there is a high incidence of development of hepatocellular carcinoma (HCC) in the process of transition from chronic hepatitis to hepatic cirrhosis. Although ginseng traditionally has been used mainly as a nutritional supplement in Asian countries, a case-control study found that it may inhibit the development of HCC. We therefore planned a clinical study of HCC prevention by medicinal ginseng. The subjects are patients with chronic C virus disease (chronic hepatitis and hepatic cirrhosis), who are high risk group for HCC. This intervention study is a multi-center, double-blind, randomized controlled trial. The participants will be randomly divided into two groups. The test sample (1 g of red ginseng powder per day) will be administered for 5 yr, and ginseng intake will be prohibited during the administration period. The primary endpoint of this study is the development of HCC. Target number of recruiting subjects are 300. The participants should be registered from February 2001 to January 2003.  (+info)

Guidelines for the treatment of recurrent and metastatic cervical cancer. (2/58)

Although there have been important advances in the management of women with cervical cancer, the optimal treatment for patients with locally recurrent and metastatic disease is still problematic, and there are relatively few randomized trials to guide treatment decisions. This paper reviews the approach to management of patients who relapse after primary treatment for cervical cancer. Patients who are still potentially curable with radical treatment are identified, and the various treatment strategies are discussed. However, most women are treated with palliative intent, and the literature on palliative management is reviewed together with the levels of evidence.  (+info)

High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. (3/58)

OBJECTIVE: To identify patient characteristics associated with the development of local recurrence and the effect of local recurrence on subsequent morbidity and mortality in patients with intermediate- to high-grade extremity soft tissue sarcomas. SUMMARY BACKGROUND DATA: Numerous studies on extremity soft tissue sarcomas have consistently shown that presentation with locally recurrent disease is associated with the development of subsequent local recurrences and that large tumor size and high histologic grade are significant factors associated with decreased survival. However, the effect of local recurrence on patient survival remains unclear. METHODS: From 1975 to 1997, 753 patients with intermediate- to high-grade extremity soft tissue sarcomas were treated at UCLA. Treatment outcomes and patient characteristics were analyzed to identify factors associated with both local recurrence and survival. RESULTS: Patients with locally recurrent disease were at a significantly increased risk of developing a subsequent local recurrence. Local recurrence was a morbid event requiring amputation in 38% of the cases. The development of a local recurrence was the most significant factor associated with decreased survival. Once a patient developed a local recurrence, he or she was about three times more likely to die of disease compared to similar patients who had not developed a local recurrence. CONCLUSIONS: Local recurrence in patients with intermediate- to high-grade extremity soft tissue sarcomas is associated with the development of subsequent local recurrences, a morbid event decreasing functional outcomes and the most significant factor associated with decreased survival. Although 85% to 90% of patients with high-grade extremity soft tissue sarcomas are treatable with a limb salvage approach, patients who develop a local recurrence need aggressive treatment and should be considered for trials of adjuvant systemic therapy.  (+info)

Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. (4/58)

BACKGROUND: In primary central high-grade osteosarcoma, a number of distinct subtypes have been identified, but little is known about the response to chemotherapy. METHODS: The authors investigated whether the subtypes correlated with histologic response to chemotherapy in 1058 patients with osteosarcoma of the extremities who were treated with neoadjuvant chemotherapy over the last 20 years. The tumors were classified as osteoblastic (70%), chondroblastic (13%), fibroblastic (9%), and telangiectatic (6%). At diagnosis, 911 patients had localized disease and 147 had resectable lung metastases. RESULTS: The response to preoperative chemotherapy was good (90% or more tumor necrosis) in 59% of patients and poor (< 90% tumor necrosis) in 41% of patients. The rate of good responses was significantly higher (P = 0.0001) in the fibroblastic (83%) and telangiectatic (80%) tumors and significantly lower in chondroblastic tumors (43%). Prognosis was significantly correlated with the histologic subtypes. The 5-year overall survival rate was significantly higher (P = 0.0001) in fibroblastic (83%) and telangiectatic (75%) tumors than in osteoblastic (62%) and chondroblastic (60%) tumors. In all subtypes, except for the chondroblastic subtype, the 5-year overall survival rate was significantly higher (P = 0.0001) in good responders P = 0.0001 (68%) than in poor responders (52%). CONCLUSIONS: The authors concluded that the histologic subtype of primary central high-grade osteosarcoma of the extremity was strictly correlated with histologic response to chemotherapy and probably, as a consequence, also with prognosis. Further studies are needed to establish whether these results justify a specific therapeutic approach based on the histologic subtype of the tumor.  (+info)

The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. (5/58)

To examine the influence of the pathology review mechanism on the results of analyses of therapeutic efficacy and biological prognostic correlates for pediatric high-grade gliomas, we evaluated the effects of using single-expert review or consensus review, as alternatives to institutional classification, in determining outcome results of a large randomized trial. The study group was the randomized cohort of Children's Cancer Group study 945, which compared efficacy of 2 chemotherapy regimens adjuvant to surgery and radiation. Trial eligibility required institutional histopathologic diagnosis of high-grade glioma. Sections of study tumors also were centrally reviewed, initially by a study review neuropathologist and subsequently by 5 neuropathologists, including the review pathologist. Reviews were independent, and reviewers were masked to clinical factors and outcomes, and consensus diagnoses of the panel were then established. Among 172 eligible patients, 42 tumors were classified as discordant on single-expert review and 51 on consensus review. Progression-free survival probabilities calculated for patients with tumors classified as high-grade gliomas by either single-expert or consensus review were inferior to those for the overall, institutionally diagnosed cohort. However, conclusions of the study regarding relative efficacy of treatment and clinical and molecular outcome correlates were unaffected by diagnosis method. Resection extent, proliferation index, and p53 expression were associated strongly with outcome, regardless of diagnosis method. However, comparisons between arms in which inclusion was determined by different review criteria for each arm caused spurious conclusions about efficacy differences between treatments. We conclude that the pathology review mechanism had little effect on within-trial comparisons of therapeutic effects or prognostic correlates in this randomized study, but strongly influenced survival distributions that were calculated for each treatment arm. These results support the implementation of expedited central review in therapeutic studies involving childhood malignant gliomas as a way to prospectively identify and exclude cases with discordant diagnoses and indicate the need for additional measures, such as molecular assessments, to increase the reproducibility of neuropathologic classification for these tumors.  (+info)

Implementing clinical protocols in oncology: quality gaps and the learning curve phenomenon. (6/58)

BACKGROUND: The quality improvement effort in clinical practice has focused mostly on 'performance quality', i.e. on the development of comprehensive, evidence-based guidelines. This study aimed to assess the 'conformance quality', i.e. the extent to which guidelines once developed are correctly and consistently applied. It also aimed to assess the existence of quality gaps in the treatment of certain patient segments as defined by age or gender and to investigate methods to improve overall conformance quality. METHODS: A retrospective audit of clinical practice in a well-defined oncology setting was undertaken and the results compared to those obtained from prospectively applying an internally developed clinical protocol in the same setting and using specific tools to increase conformance quality. RESULTS: All indicators showed improvement after the implementation of the protocol that in many cases reached statistical significance, while in the entire cohort advanced age was associated (although not significantly) with sub-optimal delivery of care. A 'learning curve' phenomenon in the implementation of quality initiatives was detected, with all indicators improving substantially in the second part of the prospective study. CONCLUSIONS: Clinicians should pay separate attention to the implementation of chosen protocols and employ specific tools to increase conformance quality in patient care.  (+info)

Probabilistic reporting of EUS-FNA cytology: Toward improved communication and better clinical decisions. (7/58)

BACKGROUND: The objectives of this study were to determine threshold probabilities needed to perform endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and those needed to treat patients suspected of having malignancy and then to compare these thresholds to the pre- and posttest probabilities of malignancy associated with benign, atypical, suspicious, and malignant diagnoses. The goal was to aid endoscopists in making appropriate clinical decisions based on both quantitative and qualitative approaches. METHODS: The study included 633 consecutive patients. A decision tree was constructed to estimate the "treatment" threshold. Using treatment threshold and likelihood ratios, the authors determined the "no-test-test" and "test-treatment" thresholds. Pretest probability was compared with no-test-test and test-treatment thresholds, and the post-EUS-FNA probability of malignancy for each diagnostic category with the treatment threshold. Results were stratified by lesion site, lesion size, and cytopathologist. RESULTS: EUS-FNA has a wide range of pretest probabilities within which it could be performed (0.06-0.98). The posttest probabilities for malignancy, 0.99 (95% confidence interval [CI], 0.967-0.996) and 0.09 (95% CI, 0.057-0.126), after a positive or a negative result, respectively, were significantly different from the treatment threshold but not those of suspicious, 0.92 (95% CI, 0.767-0.994) diagnosis. The posttest probability of atypical diagnosis, 0.60 (95% CI, 0.407-0.772), was not significantly different from that of pretest probability. Results did not vary by lesion size, organ site, or cytopathologist. CONCLUSION: The authors demonstrated the uncertainty associated with EUS-FNA diagnostic categories and used the threshold approach to qualify quantitatively the decision to perform EUS-FNA and the decision to treat patients suspected of having malignancy.  (+info)

Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. (8/58)

BACKGROUND: Adjuvant chemotherapy has been proven to be beneficial for patients with early stage non-small cell lung cancer. However, toxicity and insufficient dose delivery have been critical issues with the chemotherapy used. Doublet regimens with pemetrexed, a multi-target folate inhibitor, and platin show clear activity in non-small cell lung cancer and are well tolerated with low toxicity rates and excellent delivery. METHODS/DESIGN: In this prospective, multi-center, open label randomized phase II study, patients with pathologically confirmed non-small cell lung cancer, stage IB, IIA, IIB, T3N1 will be randomized after complete tumor resection either to 4 cycles of the standard adjuvant vinorelbine and cisplatin regimen from the published phase III data, or to 4 cycles of pemetrexed 500 mg/m2 d1 and cisplatin 75 mg/m2 d1, q 3 weeks. Primary objective is to compare the clinical feasibility of these cisplatin doublets defined as non-occurrence of grade 4 neutropenia and/or thrombocytopenia > 7 days or bleeding, grade 3/4 febrile neutropenia and/or infection, grade 3/4 non-hematological toxicity, non-acceptance leading to premature withdrawal and no cancer or therapy related death. Secondary parameters are efficacy (time to relapse, overall survival) and drug delivery. Parameters of safety are hematologic and non-hematologic toxicity of both arms. DISCUSSION: The TREAT trial was designed to evaluate the clinical feasibility, i.e. rate of patients without dose limiting toxicities or premature treatment withdrawal or death of the combination of cisplatin and pemetrexed as well as the published phase III regimen of cisplatin and vinorelbine. Hypothesis of the study is that reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and perhaps survival.  (+info)

Background:Substantial progress has been made in the multimodality treatment of soft tissue sarcoma over the past decade. This review summarizes current state-of-the-art management for patients with...
Although multimodal management of extremity soft tissue sarcoma (STS) is the standard of care, considerable variation exists in the sequencing of radiotherapy (RT) or chemotherapy (CT). Our goal was t
The association between size of the tumor and the likelihood of having significant lymphoedema (grade 2 or 3) was modeled using logistic regression. Tumor size was categorized as small or large with large representing tumors 5 cm or greater, and the small category was used as the reference for the analysis. The following variables were included as independent variables to obtain adjusted effects: age was a continuous variable, and not allowed, BMI, upper versus lower extremity, whether or not a lymph node dissection was performed, radiation, and smoking were categorical variables with male not allowed, BMI ,30 kg/m2, upper extremity, no node dissection, no radiation, and nonsmoker coded to serve as reference categories. Initially, depth of the tumor was also included as a variable; however, seeing as there were no cases of lymphoedema in the superficial group, this had to be removed from the analysis. Regression coefficients were exponentiated to determine the odds ratio (OR) of significant ...
Since publication of the first edition, Lower Extremity Soft Tissue & Cutaneous Plastic Surgery has attracted wide acclaim for its superb illustrations, clear step-by-step approach, thoroughness and practicality. Progressing from basic information on inst
Learn about Fareston (Toremifene) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
I say backlog because I started this about 5 weeks ago and figured after searching this and other forums for info I should provide my own. My history:
TY - JOUR. T1 - Bone metastasis in extremity soft tissue sarcomas. T2 - risk factors and survival analysis using the SEER registry. AU - Younis, M. H.. AU - Summers, S.. AU - Pretell-Mazzini, J.. N1 - Publisher Copyright: © 2020, Istituto Ortopedico Rizzoli. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 2020. Y1 - 2020. N2 - Introduction: While lung is the most common site of metastasis, bone metastasis of soft tissue sarcoma is a part of the natural history affecting the prognosis of these patients. To date, no studies have analyzed the histologic subtypes more likely to metastasize to bone, the risk factors for bone metastasis at initial presentation, or the effect that bone metastasis has on the survival of these patients. Material/methods: Patients were identified from the Surveillance, Epidemiology and End Results database with primary extremity STS between 2010 and 2015. Risk factors for early bone metastasis, survival based on different sites of metastasis, and ...
TY - JOUR. T1 - Adult Pilocytic Astrocytoma. T2 - An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. AU - Bond, Kamila M.. AU - Hughes, Joshua D.. AU - Porter, Amanda L.. AU - Orina, Josiah. AU - Fang, Shanna. AU - Parney, Ian F.. PY - 2018/2/1. Y1 - 2018/2/1. N2 - Introduction Pilocytic astrocytoma is a classically benign tumor that most often affects pediatric patients. Rarely, it occurs during adulthood. We present a case series and systematic literature review of adult pilocytic astrocytoma (APA) to examine the clinical presentation, extent of resection, and recurrence rate associated with this tumor in this population. Materials and Methods Our institutional records were retrospectively reviewed for cases of pilocytic astrocytoma in adults. A PubMed search identified English-language studies of pathology-proven APA. A meta-analysis was performed to determine the relationship between extent of tumor resection and recurrence. Results Forty-six ...
View details of top juvenile pilocytic astrocytoma hospitals in New Delhi. Get guidance from medical experts to select best juvenile pilocytic astrocytoma hospital in New Delhi
Find people with Juvenile Pilocytic Astrocytoma through the map. Connect with them and share experiences. Join the Juvenile Pilocytic Astrocytoma community.
Background The importance of functional outcome (FO) in the treatment of patients with extremity soft tissue sarcoma (STS) has been increasingly recognized in the last three decades. This systematic...
TY - JOUR. T1 - An elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component in the cerebellar hemisphere. AU - Sangatsuda, Yuhei. AU - Hata, Nobuhiro. AU - Suzuki, Satoshi O.. AU - Akagi, Yojiro. AU - Hatae, Ryusuke. AU - Kuga, Daisuke. AU - Yoshimoto, Koji. AU - Momosaki, Seiya. AU - Iwaki, Toru. AU - Iihara, Koji. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Pilocytic astrocytoma is a less aggressive form of glial tumor that commonly occurs in the pediatric population, and its malignant transformation is extremely rare. Here, we report an elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component. An 80-year-old male was found to have a right cerebellar non-enhanced tumor with hematoma adjoining a calcified nodule. The lesion was surgically removed, and a histological examination verified that the tumor was a malignant small cell glioma with hemorrhagic change and the calcified ...
BACKGROUND:Soft tissue sarcomas (STS) account for approximately 1% of adult malignancies, with 50 to 60% occurring in the extremities. Liposarcoma is the most common type of STS and represent about 20% of total adult sarcomas. There are rare syndromes associated with increased risk of developing STS. Further, chemical compounds such as chlorinated phenols and a few chemotherapeutic drugs have been linked to STS, along with ionizing radiation. Nevertheless, the etiology is uncertain for most of these lesions. CASE REPORT:This report details 2 cases of metachronous bilateral STS of the lower extremities. The first of these presented as a local recurrence of a previously resected right thigh liposarcoma and a new liposarcoma in the left thigh. As mentioned above, among the different subtypes of STS, liposarcoma has the highest tendency for multifocality. The second patient had multifocal metachronous leiomyosarcoma with lung metastases occurring simultaneously with the second presentation. Leiomyosarcoma
Only five spots left!. Join Laurie Hartman DO, PhD for a Special Short Notice One Day Lab Course Tuesday Sept 20th in Costa Mesa CA.. Laurie Hartman is Associate Professor of Osteopathic Technique at the British School of Osteopathy, and has been teaching osteopathic and manipulative technique and manual therapy since 1964. He is in great demand internationally and has taught and lectured in 17 different countries.. This Master Class Technique Course is limited to 10 Physical Therapists, with manual therapy experience.. Tuesday September 20th- 9am to 5pm. ...
Davis AM, OSullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel RA, Sadura A, Day A, James K, Tu D, Pater J, Zee B: Function and Health Status Outcomes in a Radomized Trial Comparing Preoperative and Postoperative Radiotherapy in Extremity Soft Tissue Sarcoma. Journal of Clinical Oncology 2002: 20: pp 4472-4477. ...
The IUPHAR/BPS Guide to Pharmacology. toremifene ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
The IUPHAR/BPS Guide to Pharmacology. toremifene ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
If someone has had chemotherapy treatments for the above mentioned (brain) tumor, does it mean he/she has cancer? I thought chemo is only to treat cancer cells, however Ive read an article that it,...
Basic Views Name:Toremifene Citrate Synonyms: FC 1157a; Fareston; NK 622; NSC 613680 CAS: 89778-27-8 Appearance: White or almost white powder Purity:98% Package: 5kg/barrel or as your inquiry Molecular Formula: C26H28ClNO·C6H8O7 Molecular Weight:...
Toremifine is an anti-oestrogen hormone that is used in the treatment of breat cancer. Read more about toremifine online at Patient
China Toremifene Citrate/CAS: 89778-27-8 Raw Powder, Find details about China Toremifene Citrate, 89778-27-8 from Toremifene Citrate/CAS: 89778-27-8 Raw Powder - Zhuhai Jiaxinkang Pharmaceutical & Chemical Co., Ltd.
https://doi.org/10.18632/oncotarget.5571 Adam M. Fontebasso, Margret Shirinian, Dong-Anh Khuong-Quang, Denise Bechet, Tenzin Gayden, Marcel Kool, Nicolas De Jay, Karine Jacob, Noha Gerges, Barbara...
Toremifene citrate increases the testosterone level over the period of administration. Most bodybuilders suffer from aromatization of steroids under an ...
Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column ...
... antineoplastic combined chemotherapy protocols MeSH E02.190.044.080 - acupressure MeSH E02.190.044.105 - acupuncture analgesia ... antineoplastic combined chemotherapy protocols MeSH E02.319.162.150 - antibiotic prophylaxis MeSH E02.319.300.253 - delayed- ... antineoplastic combined chemotherapy protocols MeSH E02.319.310.075 - antiretroviral therapy, highly active MeSH E02.319. ...
... clinical protocols MeSH N05.715.360.775.225.500 - antineoplastic protocols MeSH N05.715.360.775.235 - clinical trials MeSH ...
... is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It ... www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/7-prevention-of-antineoplastic-induced- ... but does not yet guide changes in therapy except within clinical trial protocols. Side effects of ABVD can be divided into ... nausea-and https://www.eviq.org.au/Protocol/tabid/66/id/56/view/FullView/Hodgkin+Lymphoma+Advanced+Stage+ABVD+(DOXOrubicin+ ...
The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible ... G-CSF is still included, even though the "G" is taken out of the acronym.) Amsacrine is an alkylating antineoplastic agent that ... November 1994). "FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ' ... clinical protocols and preliminary results]". Deutsche Medizinische Wochenschrift (in German). 127 (42): 2186-92. doi:10.1055/s ...
Nature Protocols, 5: 725-738, 2010. Y Zhang. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 9: 40, ... "Genotoxicity of the copper antineoplastic coordination complexes casiopeinas". Toxicology in Vitro. 25 (7): 1376-84. doi: ...
2015). "Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2 ... Cold Spring Harbor Protocols. 2016 (2): pdb.prot085118. doi:10.1101/pdb.prot085118. PMID 26832684. Sun R, Eriksson S, Wang L ( ... A standardized protocol that will help comparison of clinical studies has been suggested. Hybridomas are cells obtained by ... a biochemical strategy to enhance the activation of antineoplastic drugs". Puerto Rico Health Sciences Journal. 13 (1): 19-23. ...
Main article: List of antineoplastic agents. There is an extensive list of antineoplastic agents. Several classification ... Springer Protocols. pp. 405-432.. *^ Luqmani YA (2005). "Mechanisms of drug resistance in cancer chemotherapy". Medical ... The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs.[ ... Antineoplastic Agents in Encyclopedia of Molecular Pharmacology, 2nd Edition, Volume 1. Eds. Offermanns S and Rosenthal W. ...
Previously one could only get it from the CDC for emergency use under an expanded access IND protocol for treatment of free- ... Initial in vivo investigation on the antineoplastic activity showed positive result, but then only at high dosage and at high ... demonstrated that the antineoplastic activity of the phospholipid analogue miltefosine (at the time known as ...
... [Coordinated Undermining of Survival Paths] is one of several cancer treatment protocols using re-purposed older drugs to ... Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug ... A formal trial of the CUSP9 protocol in recurrent glioblastoma [ClinicalTrials.gov Identifier: NCT02770378] in Ulm Germany was ... Two in vitro studies confirmed strong cytotoxicity to a pannel of glioblastoma cells {8, 10}. CUSP9* treatment protocol for ...
"8.1.5: Other antineoplastic drugs". British National Formulary (BNF 57). United Kingdom: BMJ Group and RPS Publishing. March ... is also used in some mast cell tumor protocols. Unlike most of other chemotherapy agents, asparaginase can be given as an ...
Antineoplastic drugs may also increase the risk of learning disabilities among children of health care workers who are exposed ... Generating Inhibitors of P-Glycoprotein: Where to, Now?. Springer Protocols. pp. 405-432. Luqmani YA (2005). "Mechanisms of ... In the 1970s, antineoplastic (chemotherapy) drugs were identified as hazardous, and the American Society of Health-System ... A written policy needs to be in place in case of a spill of antineoplastic products. The policy should address the possibility ...
May 2020). "A Smartphone App-Based Mindfulness Intervention for Cancer Survivors: Protocol for a Randomized Controlled Trial". ... "A Systematic Review of Adherence to Oral Antineoplastic Therapies". The Oncologist. 21 (3): 354-76. doi:10.1634/theoncologist. ... JMIR Research Protocols. 9 (5): e15178. doi:10.2196/15178. PMID 32390591. National Comprehensive Cancer Network (24 November ... become an increasingly important topic of study in psycho-oncology due to the advent and proliferation of oral antineoplastics ...
Alkylating antineoplastic agents, for example, cause DNA damage, which is more harmful to cancer cells than regular cells. ... Antiseptics, anesthesia, antibiotics, better surgical techniques, evidence-based protocols and best practices continue to be ...
The new protocol that he developed led to a marked increase in disease-free survival rates for patients with medulloblastoma, ... Cisplatin is in the platinum-based antineoplastic family of medications. It works in part by binding to DNA and inhibiting its ... up to around 85%. The Packer Protocol has since become a standard treatment for medulloblastoma. Likewise, Cisplatin has been ...
See also: Antineoplastic resistance. A major cause for the ineffectiveness of current chemotherapy treatments is multiple drug ... Synthetic protocols for silver nanoparticle production can be modified to produce silver nanoparticles with non-spherical ...
Acute coronary event protocol is applied and type II can be treated similarly to type I for cardiac symptom control. Glucagon ... anti-neoplastics, glucocorticoids, nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and skin disinfectants. ... In addition to the application of the acute coronary syndrome protocol, thrombus aspiration, and placing a new stent is needed ...
The antineoplastic mustard drug canfosfamide was modeled on the structure of glutathione. Several studies have been completed ... Nature Protocols. 8 (9): 1660-9. doi:10.1038/nprot.2013.095. PMID 23928499. S2CID 22645510. Schwarzländer M, Dick T, Meyer AJ, ...
... with cisplatin or carboplatin as the backbone of all the chemotherapy treatments protocols. Pemetrexed is provided with ... and approved pembrolizumab in combination with pemetrexed and platinum-based antineoplastic (carboplatin or cisplatin) as first ...
Controversy remains as to the most effective screening protocols. For example, while some data support decreased mortality ... "Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells". Biochemical ... depending on the duration of diabetes and treatment protocol. A suspected contributor to this increased risk is circulating ...
For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive and anti-inflammatory drugs, the numbers ... agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis". Bioorganic & Medicinal Chemistry Letters ...
Some studies have shown a correlation between use of PPIs and Clostridium difficile infections. While the data are contradictory and controversial, the FDA had sufficient concern to include a warning about this adverse effect on the label of PPI drugs.[25] Concerns have also been raised about spontaneous bacterial peritonitis in older people taking PPIs and in people with irritable bowel syndrome taking PPIs; both types of infections arise in these populations due to underlying conditions and it is not clear if this is a class effect of PPIs.[25] PPIs may predispose an individual to developing small intestinal bacterial overgrowth or fungal overgrowth.[30][31] Long-term use of PPIs is associated with the development of benign polyps from fundic glands (which is distinct from fundic gland polyposis); these polyps do not cause cancer and resolve when PPIs are discontinued. There is no association between PPI use and cancer[25] or pre-cancer.[32] There is concern that use of PPIs may mask gastric ...
Staurosporine (from S. staurosporeus) also has a range of activities from antifungal to antineoplastic (via the inhibition of ... Protocols / Resources S. avermitilis genome homepage (Kitasato Institute for Life Sciences) S. coelicolor A3(2) genome homepage ... are antineoplastic (anticancer) drugs; boromycin (from S. antibioticus) exhibits antiviral activity against the HIV-1 strain of ...
"Should New Zealand continue signing up to the Pethidine Protocol?" (PDF). The New Zealand Medical Journal. 119 (1230): U1875. ...
... secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in- ...
... is also used in some treatment protocols for secondary immunodeficiencies such as human immunodeficiency ...
Heterologous polyclonal antibodies are obtained from the serum of animals (e.g., rabbit, horse), and injected with the patient's thymocytes or lymphocytes. The antilymphocyte (ALG]) and antithymocyte antigens (ATG) are being used. They are part of the steroid-resistant acute rejection reaction and grave aplastic anemia treatment. However, they are added primarily to other immunosuppressives to diminish their dosage and toxicity. They also allow transition to cyclosporin therapy. Polyclonal antibodies inhibit T lymphocytes and cause their lysis, which is both complement-mediated cytolysis and cell-mediated opsonization followed by removal of reticuloendothelial cells from the circulation in the spleen and liver. In this way, polyclonal antibodies inhibit cell-mediated immune reactions, including graft rejection, delayed hypersensitivity (i.e., tuberculin skin reaction), and the graft-versus-host disease (GVHD), but influence thymus-dependent antibody production. As of March 2005, there are two ...
Research on a progressive ratio Self-administration protocol has found amphetamine, methylphenidate, modafinil, cocaine, and ...
... protocol - protozoa - provirus - pruritus - pseudo-Cushing's syndrome - pseudovirion - PUBMED - pulmonary - purified protein ... antineoplastic - antiprotozoal - antiretroviral drugs - antisense drugs - antitoxins - Antiviral drug - aphasia - aphthous ...
"Should New Zealand continue signing up to the Pethidine Protocol?" (PDF). The New Zealand Medical Journal. 119 (1230): U1875. ...
Heterologous polyclonal antibodies are obtained from the serum of animals (e.g., rabbit, horse), and injected with the patient's thymocytes or lymphocytes. The antilymphocyte (ALG) and antithymocyte antigens (ATG) are being used. They are part of the steroid-resistant acute rejection reaction and grave aplastic anemia treatment. However, they are added primarily to other immunosuppressives to diminish their dosage and toxicity. They also allow transition to cyclosporin therapy. Polyclonal antibodies inhibit T lymphocytes and cause their lysis, which is both complement-mediated cytolysis and cell-mediated opsonization followed by removal of reticuloendothelial cells from the circulation in the spleen and liver. In this way, polyclonal antibodies inhibit cell-mediated immune reactions, including graft rejection, delayed hypersensitivity (i.e., tuberculin skin reaction), and the graft-versus-host disease (GVHD), but influence thymus-dependent antibody production. As of March 2005, there are two ...
Antineoplastic Protocols. 7/2004. Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy ...
Protocols Source:http://linkedlifedata.com/resource/pubmed/meshheading/3204009-Antineoplastic+Combined+Chemotherapy+Protocols ...
About 80 healthy non-smoking female nurses, who job it is to prepare or handle antineoplastic drugs, and a reference group of ... The protocol of the epidemiological study presented here uses an integrated environmental and biological monitoring approach. ... Statistical analysis will be performed to ascertain the association between occupational exposure to antineoplastic drugs and ... The findings of the study will be useful in updating prevention procedures for handling antineoplastic drugs. ...
Must meet protocol lab criteria which will include lab assessment of adequate bone marrow function, liver function, and renal ... History of uncontrolled heart disease within 12 months before enrollment or any protocol-defined cardiovascular abnormalities ...
Antineoplastic Combined Chemotherapy Protocols. *Drug: Cesamet™ (nabilone). Interventional. Phase 4. *NEMA Research, Inc. ...
Antineoplastic Combined Chemotherapy Protocols. *Antineoplastic Combined Chemotherapy Protocols: th. *Benzenesulfonates. * ...
Antineoplastic Combined Chemotherapy Protocols / adverse effects * Antineoplastic Combined Chemotherapy Protocols / therapeutic ...
Antineoplastic Combined Chemotherapy Protocols / therapeutic use* * Carcinoma, Ovarian Epithelial * Cluster Analysis * Drug ...
Potent, broad spectrum antineoplastic agent. Achieve your results faster with highly validated, pure and trusted compounds. ... Protocols. To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed ...
Colorectal neoplasms - diagnosis, pathology, therapy; Antineoplastic combined chemotherapy protocols; Chemotherapy, adjuvant; ...
Keywords : Leukemia, lymphoid; Antineoplastic combined chemotherapy protocols; Immunization; Viral vaccines; Child. · text in ...
Antineoplastic Protocols. *Breast Cyst. *Genes, Neoplasm. *Early Detection of Cancer. *Hereditary Breast and Ovarian Cancer ...
Cancer Treatment Protocols. *Antineoplastic protocols. *One Prior Cytotoxic Chemotherapy Regimen. *Prostatic Neoplasms ...
Antineoplastic Protocols. *Immunotherapy. *Metastatic breast cancer. *Advanced breast cancer. *Stage III to IV breast cancer ...
Antineoplastic Protocols; Breast; Breast Cyst; Breast Diseases; Breast Neoplasms; Breast Neoplasms, Male; Breast Self- ...
Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy / ... Received steroid therapy with in 7 days prior to 1st dose of study drug for anti-neoplastic intent. Received any anti (...) and ...
Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects*. Breast Neoplasms / drug therapy, ...
Antineoplastic Combined Chemotherapy Protocols / pharmacology*. Cell Death / drug effects. Cells, Cultured. Dose-Response ...
Antineoplastic Combined Chemotherapy Protocols [administration & dosage]; Cyclophosphamide [administration & dosage]; ...
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS - therapeutic use; CISPLATIN - therapeutic use; COMBINED MODALITY THERAPY; ... A pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32: ... European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638-46. DOI: http://dx. ...
Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Head and Neck Neoplasms ...
Antineoplastic Combined Chemotherapy Protocols. 1. 2014. 9799. 0.140. Why? Mutation. 2. 2014. 26651. 0.130. Why? ...
Antineoplastic combined chemotherapy protocols. With the important exception of the E4599 trial of bevacizumab in conjunction ... Cetuximab may yet show benefits for NSCLC in other treatment protocols. In particular, in vitro observations of synergy between ...
Antineoplastic Protocols CureHunter Inc. provides medical information and specifically does NOT provide medical advice. ...
Protocol. References *[1] Sin N, et al. Proc Natl Acad Sci U S A. 1997, 94(12), 6099-6103. ...
Protocol. Kinase Assay:. [1]. - Collapse. Enzyme assay and binding assay:. Protein kinase C is assayed in a reaction mixture ( ... Antineoplastic and Immunosuppressive Antibiotics inhibitor & PKC inhibitor & ADC Cytotoxin & PKA inhibitor & S6 Kinase ...
Lymphoma, Non-Hodgkin; Antineoplastic Combined Chemotherapy Protocols; Hemangiopericytoma; Meningioma; Antiretroviral Therapy, ... Carcinoma, Lobular; Biopsy; Antineoplastic Agents; Breast Neoplasms; Chemoprevention Academic: 336-716-4316. Department: 336- ... Brain Neoplasms; Glioma; Glioblastoma; Central Nervous System Neoplasms; Antineoplastic Agents Academic: 336-716-9527. ... Peritoneal Neoplasms; Hyperthermia, Induced; Chemotherapy, Cancer, Regional Perfusion; Adenocarcinoma; Antineoplastic Combined ...
Key words: Lymphoma, Extranodal NK-T-Cell; Antineoplastic Protocols; Radiotherapy; Granuloma, Lethal Midline [MeSH) ... Multiple protocols of chemotherapy are described with asparaginase, cyclophosphamide, etoposide, among others, which can be ... The patient underwent chemotherapy with SMILE protocol (Table 1). Only 2 courses of SMILE were administered with adequate ...
Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).. More From ... Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. ...
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Bayes Theorem; Biomarkers, Tumor / ...
  • The findings of the study will be useful in updating prevention procedures for handling antineoplastic drugs. (biomedcentral.com)
  • Still no agreement about the role of adjuvant radiotherapy or chemotherapy, however, protocols employed for colorectal cancer seem to be profitable in advanced and metastatic cases. (scirp.org)
  • Evaluation of surface contamination and dermal exposure to antineoplastic drugs will be assessed by determining cyclophosphamide on selected surfaces (wipes) and on the exposed nurses' clothes (pads). (biomedcentral.com)
  • Intraperitoneal antineoplastic drug delivery: experience with a cyclophosphamide, vincristine and prednisolone protocol in cats with malignant lymphoma. (semanticscholar.org)
  • Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. (gu.se)
  • Biological monitoring methods have been developed to detect occupational exposure to antineoplastic agents [ 17 ]. (biomedcentral.com)
  • It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. (nih.gov)
  • Several management options are available to treating physicians: discontinuation of chemotherapy, premedication, prolonging of infusion duration, desensitization protocols, and replacement with a different platinum compound after performing skin tests that rule out cross-reactions among platinum agents. (hindawi.com)
  • Syrigou E, Syrigos K, Saif MW (2008) Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. (springer.com)
  • Antineoplastic agents interfere with cell reproduction. (medscape.com)
  • Cellular apoptosis (ie, programmed cell death) is also a potential mechanism of many antineoplastic agents. (medscape.com)
  • Following administration of antineoplastic agents, serotonin (5-HT) is released from enterochromaffin cells in the GI tract. (medscape.com)
  • Antineoplastic agents may cause nausea and vomiting so intolerable that patients may refuse further treatment. (medscape.com)
  • Some antineoplastic agents are more emetogenic than others. (medscape.com)
  • Which medications in the drug class Antineoplastic agents are used in the treatment of Pancreatic Cancer? (medscape.com)
  • Aminoacridine derivative that is a potent intercalating antineoplastic agent. (nih.gov)
  • Amsacrine is an aminoacridine derivative that is a potent intercalating antineoplastic agent. (drugbank.ca)
  • The treatment and the maintenance doses of Procarbazine should be determined only by a physician experienced in the use of potent antineoplastic drugs in children. (medicines.org.uk)
  • Procarbazine is indicated in the treatment of Hodgkin's lymphoma in children aged 2-18, when associated with other antineoplastic drugs in an appropriate protocol. (medicines.org.uk)
  • Another option is to use desensitization protocols that induce a temporary state of tolerance by gradually administering small quantities of the antineoplastic drug until the therapeutic dosage is reached. (springer.com)
  • Statistical analysis will be performed to ascertain the association between occupational exposure to antineoplastic drugs and biomarkers of DNA and chromosome damage, after taking into account the effects of individual genetic susceptibility, and the presence of confounding exposures. (biomedcentral.com)
  • Antineoplastics 2018-06-02 00:00:00 Reactions 1704, p39 - 2 Jun 2018 Various toxicities: case report A 9-month-old boy developed neutropenia, fungal infection, typhlitis and sepsis during induction chemotherapy with initial prednisolone followed by dexamethasone, daunorubicin, vincristine, asparaginase and cytarabine for B cell acute lymphoblastic leukaemia [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. (deepdyve.com)
  • Subsequently, he was started on induction chemotherapy consisting of initial eight days treatment with prednisolone followed by dexamethasone, daunorubicin, vincristine, asparaginase and cytarabine as per Children's Oncology Group Infant Protocol. (deepdyve.com)
  • An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. (bioportfolio.com)
  • Vinblastine derivative with antineoplastic activity against CANCER. (bioportfolio.com)
  • ensure the medical officer administering the antineoplastic drugs signs the medication order indicating that they have administered the drug(s). (eviq.org.au)
  • The aim is to assess in hospital nurses preparing and/or administering therapy to cancer patients the current level of occupational exposure to antineoplastic drugs, DNA and chromosome damage as cancer predictive effects, and the association between the two. (biomedcentral.com)
  • Authoritative and essential, RNA Interference and Cancer Therapy: Methods and Protocols provides the necessary guidance for both novice and professional researchers who intend to discover and innovate newer means of using RNAi technology to combat cancer, one of the greatest scourges of human health. (springer.com)
  • Doxorubicin (DOX) is a common antineoplastic anthracycline antibiotic and is used for treatment of many types of cancer [ 1 ]. (hindawi.com)
  • Hypersensitivity reaction (HSR) to antineoplastic drugs can force doctors to stop treatment and seek other alternatives. (springer.com)
  • The inclusion criteria were patients undergoing chemotherapy treatment with oxaliplatin who had developed an HSR to the drug and who were candidates for continuing the treatment using a desensitization protocol. (springer.com)
  • The patients' clinical records were reviewed and variables were gathered relating to the patient, the treatment, the HSR, and the desensitization protocol administered. (springer.com)
  • This study confirms that oxaliplatin desensitization protocols are safe and effective and allow patients to continue with the treatment that initially caused an HSR. (springer.com)
  • Changes in the nail unit are common during treatment with antineoplastic drugs. (eviq.org.au)
  • This protocol may be of value to those patients requiring praziquantel treatment with a history of IgE-mediated allergy to the drug. (ajtmh.org)
  • About 80 healthy non-smoking female nurses, who job it is to prepare or handle antineoplastic drugs, and a reference group of about 80 healthy non-smoking female nurses not occupationally exposed to chemicals will be examined simultaneously in a cross-sectional study. (biomedcentral.com)
  • This has lead several organizations to develop guidelines or recommendations with the aim to improve safety during the handling of antineoplastic drugs and reduce risk of contamination in the workplace [ 21 - 23 ]. (biomedcentral.com)
  • Accordingly, several antineoplastic drugs have been classified by the International Agency of Research on Cancer (IARC), on the basis of epidemiological reports, animal carcinogenicity data, as well as the outcomes of in vitro genotoxicity studies, as definite (Group 1), probable (Group 2A) or possible (Group 2B) human carcinogens [ 26 - 29 ]. (biomedcentral.com)
  • The consequences of inadvertently administering antineoplastic drugs not intended for intrathecal or intraventricular use can be FATAL . (eviq.org.au)
  • This clinical procedure outlines the care of the patient pre, during and post lumbar puncture and administration of intrathecal antineoplastic drugs and the equipment required for this procedure. (eviq.org.au)
  • Only health care professionals specifically trained, accredited and experienced in cancer treatments should be designated to prescribe, prepare, dispense, deliver, receive, check or administer intrathecal antineoplastic drugs. (eviq.org.au)
  • This paper presents the protocol for a Phase 3 multi-site randomised controlled trial evaluating a novel nurse-led Telehealth intervention for remote monitoring/management of chemotherapy side-effects in Australian haematological cancer patients. (strath.ac.uk)
  • A total of 53 desensitization protocols were administered to 21 patients. (springer.com)
  • All patients were able to complete the desensitization protocol. (springer.com)
  • any unused antineoplastic drug that has been opened should be discarded appropriately or alternatively, if not removed from packaging, must be returned to the oncology pharmacy for storage. (eviq.org.au)
  • The Nordic Society of Paediatric Haematology and Oncology (NOPHO)-AML protocols use higher cumulated doses of cytarabine and more chemotherapy series (n = 6) than other protocols with the potential increased risk of severe VGS infections. (forskningsdatabasen.dk)
  • The aim of this study is to assess the effectiveness of oxaliplatin desensitization protocols. (springer.com)
  • Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. (hindawi.com)
  • Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. (springer.com)
  • As the protocol is from Canada- some Medications not typically used in the US. (aphon.org)
  • The work Recombinant antibodies for cancer therapy : methods and protocols represents a distinct intellectual or artistic creation found in University of Missouri Libraries . (missouri.edu)
  • In Recombinant Antibodies for Cancer Therapy: Methods and Protocols, Martin Welschof and Jürgen Krauss present a collection of carefully selected protocols for the design, construction, and characterization of those novel anticancer therapeutics. (missouri.edu)
  • Streptozotocin or streptozocin (INN, USP) (STZ) is a naturally occurring alkylating antineoplastic agent that is particularly toxic to the insulin-producing beta cells of the pancreas in mammals. (fiqhcouncil.org)
  • Other appropriate applications include work with antineoplastic drugs, genetic material, asbestos and additional substances that generate hazardous airborne particulates. (labconco.com)